ETF & Mutual Fund, Research

Health Care ETFs

Osbert Bryan, Senior Fund Research Analyst
08 May 2024


The U.S. health care industry endured challenging conditions in 2023, including persistently high inflation rates, labor market struggles, and recovery from the Covid-19 pandemic. CFRA expects 2024 to be the year of gradual recovery for biopharmaceuticals as we expect to see improved revenue and margin performance.

Want to learn more? Download the Report.


Fundamental Equity Research
Gain a comprehensive view of global themes, industries, and companies.

Related Insights

A Case for Global Bond ETFs

A Case for Global Bond ETFs

Diversification within a fixed income portfolio using global bonds could be advantageous given the current...
Read more